{"id":"W2263154823","doi":"10.3899/jrheum.140831","title":"Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ixekizumab; Rheumatoid arthritis; Discontinuation; Internal medicine; Rheumatology; Adverse effect; Arthritis; Tumor necrosis factor alpha; Immunology; Gastroenterology; Psoriatic arthritis; Secukinumab","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001901549,0.0008126875,0.001432087,0.0003077648,0.0003724795,0.0005792698,0.000587501,0.0009922698,0.002486301],"category_scores_gemma":[0.001776885,0.0004422467,0.001081767,0.000238024,0.0007081736,0.0007344462,0.0002535777,0.001845583,0.0005228372],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003524089,"about_ca_system_score_gemma":0.0006308182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002265702,"about_ca_topic_score_gemma":0.0004855373,"domain_scores_codex":[0.9993047,0.0003984738,0.00005510563,0.00009103162,0.00007254684,0.00007818575],"domain_scores_gemma":[0.9985586,0.0003662986,0.0004326955,0.0001340942,0.00007806093,0.0004302065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7990423,0.04929157,0.01150121,0.0007936286,0.0007691363,0.0002671943,0.0002584932,0.000873386,0.02344147,0.00007450918,0.0006406127,0.1130464],"study_design_scores_gemma":[0.5085305,0.4665817,0.02094923,0.00003935364,0.0002431279,0.0002593497,0.00004424311,0.0006308224,0.001763537,0.0000590348,0.0008777911,0.00002125534],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965224,0.001765633,0.0003606551,0.0001023454,0.00005264837,0.0005975303,0.000168785,0.00003239945,0.0003975493],"genre_scores_gemma":[0.9956675,0.0008152773,0.001068858,0.000256788,0.0001620137,0.0009078697,0.0004554332,0.000008082294,0.0006582773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002486301,"threshold_uncertainty_score":0.0100565,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03339726482724165,"score_gpt":0.3263880893274043,"score_spread":0.2929908245001626,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}